SecBot SecBot
6-K ·Filed Mar 26, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0001575872-26-000166
Notable filing: 6-K
Actionable Insight • Neutral

No immediate trading implications. Monitor for any pattern of ESOP exercises which could indicate employee sentiment, but this isolated event is immaterial to share value.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.77
T+0 close · Mar 26, 2026 · via day close
Latest settled
+1.89%
T+60 · $14.03
Vs SPY
−12.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $13.77entry
  2. T+1 · 8mo ago −2.11%α −0.43% · $13.48
  3. T+5 · 8mo ago −3.27%α −4.90% · $13.32
  4. T+20 · 7mo ago −0.73%α −11.39% · $13.67
  5. T+60 · 5mo ago +1.89%α −12.06% · $14.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's Laboratories issued 3,675 equity shares on March 26, 2026, following the exercise of stock options under its 2007 ESOP scheme. The shares were allotted at par value of Re.1 each, with 3,100 shares issued at an exercise price of Rs. 735.80 each.

Key Facts

  • Company allotted 3,675 fully paid equity shares of Re.1 each on March 26, 2026
  • Shares were issued pursuant to the Dr. Reddy's Employees ADR Stock Options Scheme, 2007
  • 575 shares issued at Re.1 each, 3,100 shares issued at Rs. 735.80 each
  • Total issued share capital increased to 83,46,57,970 shares
  • Filing made under SEBI Listing Obligations & Disclosure Requirements Regulations, 2015

Financial Impact

Minimal financial impact - issuance of only 3,675 shares represents less than 0.005% of total outstanding shares

share_countequity_capital

Risk Factors

  • Minimal dilution effect from new share issuance
  • Potential perception of insider selling if option holders immediately sell shares

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000166
Document: 0001575872-26-000166-index.html0001575872-26-000166
Document: 0001575872-26-000166.txt0001575872-26-000166

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026